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Abstract: 
Introduction: Studies suggest that enzymes involved in the estrogen metabolic pathway 
are susceptibility factors for breast cancer; however, there is limited direct evidence in 
relation to estradiol levels. The glutathione-S-transferase M1 enzyme (GSTM1) enzyme 
is involved in estrogen peroxidation, and a shortage seems to enhance estrogen exposure. 
A homozygous deletion of the GSTM1 gene leads to total absence of enzyme activity, 
and studies indicate that an association with breast cancer risk may be modified by body 
mass. So far, parallel studies on intermediate biomarkers (i.e. estradiol) are largely 
missing. Thus, in the present study, we assessed the association between a GSTM1 
genetic polymorphism (null/rs1065411) and daily salivary levels of 17-βestradiol 
throughout one entire menstrual cycle and evaluated modification of genotype effects 
according to metabolic profile in 190 premenopausal women aged 25-35 years. 
Methods: The women participated in the Energy Balance and Breast Cancer Aspects 
study (EBBA-I, 2000-2002) in Tromsø, North Norway (inclusion criteria: healthy, non-
pregnant, non-lactating, no current use of exogenous hormones). Salivary levels of 17-
βestradiol were assessed by radioimmunoassay (The Reproductive Ecology Laboratory, 
Harvard University). Height and weight were measured. Genomic DNA was extracted 
from EDTAwhole blood. GSTM1 genotyping was done on the ABI PRISM® 3100 
Genetic Analyzer (Fred Hutchinson Cancer Research Center). The GSTM1 assay 
distinguishes between the GSTM1*Aallele (G nucleotide, Lys at aminoacid 173), the 
GSTM1*B allele (C nucleotide, Asn at aminoacid 173), and the homozygous gene 
deletion. Regression models were used to study the relation between genetic (null 
genotype versus all other alleles combined) and metabolic susceptibility factors, and 
levels of 17-βestradiol. 
Results: Mean body mass index (BMI) was 24.4 kg/m2. The homozygous gene deletion 
of GSTM1 had a prevalence of 52%, and the frequency of the null genotype was similar 
in heavy women (BMI ≥26.3 kg/m2, upper quartile) as compared to other women (p = 
.18). The null genotype was associated with lower levels of 17-βestradiol by cycle day 
compared to other alleles (p = .04). However, the association was confined to women that 
were normal weight to slightly overweight (p for interaction = .01). In women with BMI 
< 26.3 kg/m2, the null genotype was associated with significantly lower levels of 17-
βestradiol by cycle day compared to other alleles (p = .02) and an 18% reduction in 
overall average level of 17-β estradiol throughout the cycle (p = .02), while in heavy 
women no association with estradiol levels was observed.  
Conclusion: In our study, GSTM1 genotype was a significant determinant of circulating 
estradiol levels in premenopausal women without marked adiposity. Thus, interestingly 
our results strongly support that the effect of body mass on estradiol levels and 
subsequent breast cancer development may be modified by GSTM1 genotype. 